Apimeds Pharmaceuticals US (APUS) Change in Cash (2024 - 2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Change in Cash came in at -$5.3 million in Q4 2025, down 23043.98% YoY from N/an in Q4 2024, and down 205.94% on a QoQ basis from -$1.7 million in Q3 2025.
Apimeds Pharmaceuticals US (APUS) Change in Cash (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has 2 years of Change in Cash data on file, last reported at -$5.3 million in Q4 2025.
- Quarterly Change in Cash fell 23043.98% year-over-year to -$5.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.6 million (up 501.25% YoY) and the FY2025 annual result came in at $1.6 million, up 501.25% from the prior year.
- Change in Cash retreated to -$5.3 million in Q4 2025, from -$1.7 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $8.5 million in Q2 2025 to a low of -$5.3 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -86.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -465.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -881.03 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 523.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -915.70 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 64.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 102.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Apimeds Pharmaceuticals US | 7.68 Mn | 7.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.35 Mn |
| Sep 30, 2025 | -1.75 Mn |
| Jun 30, 2025 | 8.48 Mn |
| Mar 31, 2025 | 246,887.00 |
| Dec 31, 2024 | -23,116.00 |
| Sep 30, 2024 | -36,755.00 |
| Jun 30, 2024 | -84,055.00 |
| Mar 31, 2024 | -263,100.00 |